FUAD S SHIHAB

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology SALT LAKE CITY, UT NPI 1700976321

General Payments — all program years on this page

$108,535.19

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 115
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $24,358.67 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $23,071.6611
Food and Beverage $738.203
Travel and Lodging $548.812

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $28,000.9238
2019 $26,728.2420
2020 $6,939.4014
2021 $5,262.005
2022 $16,373.4618
2023 $872.504
2024 $24,358.6716

Records — PY2024 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087331215 Novartis Pharmaceuticals Corporation $551.26 10/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087331217 Novartis Pharmaceuticals Corporation $57.83 10/27/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1087331219 Novartis Pharmaceuticals Corporation $3,900.00 10/27/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1087331221 Novartis Pharmaceuticals Corporation $490.98 10/27/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1087331223 Novartis Pharmaceuticals Corporation $1,625.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093951198 Alexion Pharmaceuticals, Inc. $83.90 10/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105906687 VERTEX PHARMACEUTICALS INCORPORATED $293.33 07/03/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1117381752 Amgen Inc. $103.04 10/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137674875 Takeda Pharmaceuticals U.S.A., Inc. $600.00 01/16/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1139166441 RECORDATI_RARE_DISEASES_INC. $12,420.00 08/20/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1139166443 RECORDATI_RARE_DISEASES_INC. $1,890.00 12/04/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1139166445 RECORDATI_RARE_DISEASES_INC. $540.00 12/04/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1139166447 RECORDATI_RARE_DISEASES_INC. $810.00 12/04/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1144714481 TerSera Therapeutics LLC $380.00 04/16/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1147468061 ZOLL Medical Corporation $200.00 01/26/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1147468067 ZOLL Medical Corporation $413.33 01/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.